Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Каталог · ЕАЭС

Клинические исследования и проекты

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · найдено 24

Ищем по всем вариантам написания в реестрах, по-русски и по-английски. Спонсор или разработчик.
Статус
Что исследуют
Источник
Фаза
Страна
Участники
Кто может участвовать По критериям ClinicalTrials.gov. Исследования, где реестр возраст и пол не указывает, тоже показываются. Возраст и пол нигде не сохраняются.
Сбросить
24 исследования
Статус неизвестен Фаза III Здоровые добровольцы Беларусь
Gam-COVID-Vac · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Сlinical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-СoV-2 Infection Prophylactic Treatment in Republic of Belarus

Минск, Витебск 8 центров 100 участников во всех странах ClinicalTrials.gov 04-Gam-COVID-Vac-2020-RB
Завершено Фаза I–II Здоровые добровольцы Россия
Gam-COVID-Vac Lyo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac Lyo" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers

Москва 1 центр 38 участников во всех странах ClinicalTrials.gov 03-Gam-COVID-Vac Lyo-2020
Завершено Фаза II Здоровые добровольцы Россия
GamFluVac · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product With a Period of Open Safety Assessment in Two Modes of Administration, in Healthy Volunteers

Москва 1 центр 224 участника во всех странах ClinicalTrials.gov 03 - GamFluVac-2019
Статус неизвестен Фаза II–III Здоровые добровольцы Россия
Gam-COVID-vac M; Placebo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Label Study With an Open Dose Selection Period to Assess the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac, a Combined Vector Vaccine for the Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Virus", With the Participation of Adolescent Volunteers

Москва 2 центра 3 000 участников во всех странах ClinicalTrials.gov OLSTAD
Статус неизвестен Фаза I–II Здоровые добровольцы Россия
Vaccine GamLPV · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Randomized Double-blind Placebo-controlled Comparative Research of Potency and Safety of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine, Using Two Dosing Schedules and Methods of Application in Healthy Human Volunteers

Москва 1 центр 50 участников во всех странах ClinicalTrials.gov GamLPV-02
Завершено Фаза I–II Здоровые добровольцы Россия
Gam-COVID-Vac · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers

Москва 1 центр 38 участников во всех странах ClinicalTrials.gov 02-Gam-COVID-Vac-2020
Завершено Фаза I Здоровые добровольцы Россия
Fluorothyazinone 300 mg; Fluorothyazinone 600 mg; Fluorothyazinone 3900 mg · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone Used as a Single-Dose Administration or a Treatment Course in Healthy Volunteers

Москва 1 центр 25 участников во всех странах ClinicalTrials.gov 02-FT-2017
Завершено Здоровые добровольцы Россия
02 - GamEvac-Combi-2016 · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Open Study of the Duration of Immunity After Vaccination With Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose

Санкт-Петербург 1 центр 60 участников во всех странах ClinicalTrials.gov 02 - GamEvac-Combi-2016
Идёт Фаза III Здоровые добровольцы Россия
GamTBvac; Placebo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of the GamTBvac Recombinant Subunit Tuberculosis Vaccine for the Prevention of Non-HIV-associated Pulmonary Tuberculosis in Volunteers Aged 18 Years and Older.

Санкт-Петербург 1 центр 9 500 участников во всех странах ClinicalTrials.gov 02-GamTBvac-2020
Статус неизвестен Фаза II Здоровые добровольцы Россия
Gam-COVID-Vac · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Study of the Safety, Tolerability and Immunogenicity of the "Gam-COVID-Vac"Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years

Москва 1 центр 110 участников во всех странах ClinicalTrials.gov 05-Gam-COVID-Vac-2020
Завершено Фаза I–II Здоровые добровольцы Россия
GamEvac-Lyo (component A); GamEvac-Lyo (component B); GamEvac-Lyo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product GamEvac-Lyo, Vector-Based Vaccine Against Ebola Virus Disease, Lyophilisate for Preparation of Solution for Intramuscular Injection

Санкт-Петербург 1 центр 220 участников во всех странах ClinicalTrials.gov 01-GamEvac-Lyo-2017
Завершено Фаза IV Здоровые добровольцы Россия
GamEvac-Combi (vaccine); Placebo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

01 - GamEvac-Combi-2016 " International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose "

Москва 1 центр 2 000 участников во всех странах ClinicalTrials.gov 01 - GamEvac-Combi-2016
Завершено Фаза II Здоровые добровольцы Россия
GamTBvac vaccine; placebo · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

A Double-blind, Randomized, Multicentre, Placebo-controlled Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac in Healthy Adults

Москва 2 центра 180 участников во всех странах ClinicalTrials.gov 01-GamTBvac-2018
Завершено Фаза II Россия
Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim; Ftortiazinon (tablets 300 mg) full dose + Maxipim · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Randomized, Blind, Placebo-controlled Study to Evaluate Safety and Efficacy of Ftortiazinon in Combination With Maxipime®, in Comparison With Placebo in Combination With Maxipime®, in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

Санкт-Петербург, Всеволожск 5 центров 777 участников во всех странах ClinicalTrials.gov 04-FT-2018
Завершено Фаза I Здоровые добровольцы Россия
Vaccine GamLPV · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine; A Randomized Placebo-controlled Dose-escalating Study of Single-use GamLPV Safety and Tolerability in Healthy Human Volunteers

Москва 1 центр 36 участников во всех странах ClinicalTrials.gov GamLPV-01
Статус неизвестен Фаза I–II Здоровые добровольцы Россия
BVRS-GamVac · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Double-blind, Placebo-controlled Study With an Open Dose Selection Period for Assessing the Safety and Immunogenicity of the Drug "BVRS-GamVac", a Vector Vaccine for the Prevention of the Middle East Respiratory Syndrome, Lyophilisate for the Preparation of a Solution for Intramuscular Administration, With the Participation of Healthy Volunteers

Санкт-Петербург 1 центр 162 участника во всех странах ClinicalTrials.gov 01-BVRS-GamVac-2019
Статус неизвестен Фаза I–II Здоровые добровольцы Россия
Sputnik Light · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

An Open Study on the Safety, Tolerability, and Immunogenicity of "Sputnik Light" t Vaccine for Prevention of Coronavirus Infection Caused by the SARS-CoV-2 Viruso

Санкт-Петербург 1 центр 110 участников во всех странах ClinicalTrials.gov 06 - Sputnik Light - 2020

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.